SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. Financials Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Equities
6990
CNE1000062J1
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 147.6 HKD | +3.80% |
|
-9.67% | +43.44% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 20,501 | 30,542 | - | - |
| Enterprise Value (EV) 2 | 19,042 | 29,967 | 29,768 | 29,567 |
| P/E ratio | -33.4 x | -50.6 x | -47.6 x | -526 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 13.3 x | 25 x | 19.7 x | 11.9 x |
| EV / Revenue | 12.4 x | 24.6 x | 19.2 x | 11.6 x |
| EV / EBITDA | -57.9 x | -55 x | -57.2 x | 108 x |
| EV / FCF | -839 x | -34.1 x | -44.9 x | -160 x |
| FCF Yield | -0.12% | -2.94% | -2.23% | -0.63% |
| Price to Book | 7.48 x | 17.9 x | 26.1 x | 15.9 x |
| Nbr of stocks (in thousands) | 219,195 | 222,844 | - | - |
| Reference price 3 | 102.9 | 147.6 | 147.6 | 147.6 |
| Announcement Date | 3/25/24 | - | - | - |
1HKD in Million2CNY in Million3HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 1,540 | 1,220 | 1,548 | 2,559 |
| EBITDA 1 | - | -328.6 | -544.9 | -520.7 | 274.7 |
| EBIT 1 | - | -383.4 | -670.5 | -715.4 | -213.3 |
| Operating Margin | - | -24.89% | -54.97% | -46.23% | -8.34% |
| Earnings before Tax (EBT) 1 | - | -467.7 | -594.5 | -598.6 | -0.144 |
| Net income 1 | -616.1 | -574.1 | -570.6 | -608.6 | -33.79 |
| Net margin | - | -37.27% | -46.78% | -39.33% | -1.32% |
| EPS 2 | -6.201 | -3.080 | -2.914 | -3.104 | -0.2808 |
| Free Cash Flow 1 | - | -22.69 | -880 | -663.4 | -184.9 |
| FCF margin | - | -1.47% | -72.15% | -42.87% | -7.23% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 6/28/23 | 3/25/24 | - | - | - |
1CNY in Million2HKD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|
| Net sales 1 | 1,046 | 494.3 | 854.8 | 663 |
| EBITDA | - | - | - | - |
| EBIT 1 | 95.89 | -503.4 | -179 | -642.3 |
| Operating Margin | 9.17% | -101.85% | -20.94% | -96.88% |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | - | - | - | - |
| Net margin | - | - | - | - |
| EPS 2 | -0.1829 | -2.896 | -1.170 | -3.270 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 8/28/23 | 3/25/24 | - | - |
1CNY in Million2HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 1,459 | 575 | 774 | 976 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -22.7 | -880 | -663 | -185 |
| ROE (net income / shareholders' equity) | - | - | -30.2% | -65.8% | -22.9% |
| ROA (Net income/ Total Assets) | - | -25.5% | -23.4% | -25.1% | 7.33% |
| Assets 1 | - | 2,251 | 2,441 | 2,429 | -460.8 |
| Book Value Per Share 2 | - | 13.80 | 8.250 | 5.650 | 9.280 |
| Cash Flow per Share 2 | - | 0.3500 | -2.880 | -0.2400 | 4.870 |
| Capex 1 | - | 82.3 | 133 | 140 | 143 |
| Capex / Sales | - | 5.34% | 10.9% | 9.04% | 5.57% |
| Announcement Date | 6/28/23 | 3/25/24 | - | - | - |
1CNY in Million2HKD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
147.6
HKD
Average target price
201.2
HKD
Spread / Average Target
+36.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.44% | 4.21B | |
| +20.12% | 126B | |
| +25.25% | 119B | |
| +25.56% | 27.95B | |
| -19.51% | 20.5B | |
| -14.36% | 17.12B | |
| -15.63% | 16.1B | |
| -46.67% | 14.97B | |
| +11.89% | 14.84B | |
| +57.74% | 14.38B |
- Stock Market
- Equities
- 6990 Stock
- Financials Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
